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A commentary on 35	  
Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect 36	  
against Atherosclerosis by Induction of Regulatory T Cells 37	  
by Yun TJ, et al. Cell Metab (2016) 23(5):852-66. doi: 10.1016/j.cmet.2016.04.010. Correction: 38	  
Cell Metab (2016) 24(6):886. doi: 10.1016/j.cmet.2016.11.008. 39	  
 40	  
Plasmacytoid dendritic cells (pDCs) are a unique subset of dendritic cells gaining increasing 41	  
interest in atherosclerosis because of their ability to influence disease progression through a 42	  
broad range of activities. Positioned at the border between innate and adaptive immunity, pDCs 43	  
are found in lymphoid and somatic tissues where they play different roles depending on 44	  
anatomical location and context (1). 45	  
Several lines of evidence in recent years have highlighted the contribution of pDCs to the 46	  
development of atherosclerosis. Circulating pDCs are reduced in patients with coronary and 47	  
peripheral artery disease (1, 2); on the contrary, although scarce, pDCs become detectable in 48	  
human atherosclerotic lesions, where their levels are either considered to be stable (based on 49	  
blood dendritic cell antigen 2 (BDCA2) staining) or tend to increase (based on CD123 staining) 50	  
with disease progression (1, 3-5). A recent study also suggested a causal association between 51	  
pDC-derived type I IFN and the development of atherosclerosis in systemic lupus 52	  
erythematosus (6). 53	  
Results from experimental animal studies were more conflicting; however, most of the data 54	  
point towards a detrimental role played by pDCs in atherosclerosis. Initially, using an antibody-55	  
mediated depletion model, pDCs were shown to protect against atherosclerosis and vascular 56	  
response to injury, induced by bilateral placement of semiconstrictive collars in the carotid 57	  
arteries of low-density lipoprotein receptor (Ldlr)-/- mice (3). However, subsequent studies 58	  
demonstrated that antibody-mediated depletion of pDCs inhibited experimental atherosclerosis 59	  
in apolipoprotein-E (apoE)-/- mice (4, 7). More recently, by using a CD11c-restricted deletion of 60	  
the transcription factor Tcf4/E2-2, which is required for pDC development and maintenance, 61	  
pDC deficiency was shown to reduce plaque formation in Ldlr-/- chimeras (8). This phenotype 62	  
was confirmed in chimeras lacking the pIII and IV promoters of MHC-II transactivator (CIITA) 63	  
in pDCs, leading to MHC-II-restricted antigen presentation defects in pDCs. This data supports 64	  
a proatherogenic role for pDCs in experimental atherosclerosis and identifies a critical role 65	  
played by pDCs in sustaining atherogenic T cell response(s). 66	  
The pro-atherogenic role of pDCs has been challenged by a recent article published in Cell 67	  
Metabolism (9), where the authors suggest that pDCs may exert a tolerogenic role in 68	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experimental atherosclerosis, being able to decrease plaque progression via induction of 69	  
regulatory T cells (Tregs). 70	  
The authors performed a difficult and elegant work in the identification of a defined pure 71	  
population of pDCs in the mouse aorta, being able to demonstrate for the first time, the capacity 72	  
of aortic murine and human pDCs to produce type I IFN in both healthy and atherosclerotic 73	  
vessels. The authors confirmed the scarce presence and anatomical location of pDCs in the 74	  
intimal space and adventitia, as previously demonstrated (3, 7, 8); moreover total aortic pDC 75	  
numbers increased with atherosclerosis progression. 76	  
Importantly, the authors demonstrated that treatment with pDC-targeting Ab (plasmacytoid 77	  
dendritic cell antigen-1 (BST2/PDCA-1/CD317)), previously used to investigate pDCs in 78	  
experimental atherosclerosis, was not fully selective, leading to partial (albeit not significant) 79	  
aortic macrophage depletion. Previous immunofluorescence staining of aged apoE-/- mouse 80	  
atherosclerotic arteries in our hands, showed that a significant number of PDCA-1+ cells were 81	  
present in the T cell area of arterial tertiary lymphoid organs (ATLOs), with localization of 82	  
PDCA-1 also observed in endothelial cells of high endothelial venules (10). Yun et al. (9) work 83	  
complement our studies, directly demonstrating that antibody mediated pDC depletion should 84	  
be avoided in atherosclerosis research, given that PDCA-1 is promiscuously expressed in the 85	  
vascular inflammatory environment. 86	  
The key experiments performed by the authors to assess pDC contribution to experimental 87	  
atherosclerosis present incongruences that merit discussion: 88	  
 89	  
Efficacy of pDC Depletion After Prolonged Treatment in BDCA2-DTR Mice 90	  
To explore the role of pDCs in plaque formation, they generated atherosclerotic chimeric mice 91	  
by reconstituting Ldlr-/- mice with bone marrow (BM) from BDCA2-DTR mice. These 92	  
transgenic mice express a simian diphtheria toxin receptor (DTR) under the transcriptional 93	  
control of the human pDC gene promoter BDCA2 (11). In these animals, pDCs 94	  
(SiglecH+B220+) are successfully and selectively depleted 24h after diphtheria toxin treatment 95	  
(DT; administered intraperitoneally (i.p.) at 100-120 ng/mouse) (11). In the original research 96	  
article, DT-induced depletion persisted for 2-3 days (11). It was also suggested that pDCs could 97	  
be depleted for longer periods with repeated DT administration but no data were shown to 98	  
support this statement. Several other studies have used BDCA2-DTR mice; nevertheless, only 99	  
one of those studies depleted pDCs for more than 2-3 weeks. In particular, pDCs were said to be 100	  
depleted in BDCA2-DTR mice for 8 weeks in a lupus model; however, only splenic depletion 101	  
data at 24h and 72h were shown (12). 102	  
More recently, BDCA2-DTR mice have been crossed with apoE-/- mice to generate apoE-/- 103	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BDCA2-DTR mice for the investigation of pDCs in atherosclerosis (13). DT administration to 104	  
induce pDC depletion for 4 weeks (0.01 mg/kg administered i.p. 3 times per week) during high 105	  
fat diet (HFD) did not affect lesion formation in the aortic sinus. Importantly, detailed analysis 106	  
of depletion efficiency demonstrated complete pDC depletion for one week only. After four 107	  
weeks of continuous DT administration, pDCs failed to express DTR anymore and therefore 108	  
could not be depleted. On the contrary, the authors showed an increase of B cells in all organs, 109	  
accompanied by changes of the inflammatory profile in pDC ‘depleted’ mice compared to 110	  
controls. Although we cannot exclude that the breeding of BDCA2-DTR mice to apoE-/- may 111	  
have contributed to altered pDC depletion, the available data highlight the importance to 112	  
carefully evaluate depletion efficiency in long-term experiments with BDCA2-DTR mice. 113	  
Yun et al. (9) used chimeric Ldlr-/-:BDCA2-DTR mice fed with HFD for 12 weeks, with or 114	  
without DT treatment (0.5 µg/mouse per week, i.p.), to deplete pDCs. Atherosclerotic plaque 115	  
formation significantly increased in the sinus of pDC-depleted animals. Depletion efficiency 116	  
was shown in BDCA2-DTR mice administered with DT twice at 24h intervals. Similarly, 117	  
selective depletion was shown in Ldlr-/-:BDCA2-DTR mice; however, the time point of 118	  
assessment of aortic and spleen pDC depletion was not reported in the original manuscript. 119	  
Subsequently, data showing partial pDC depletion in the spleen, after 12 weeks of DT injection, 120	  
have been added as corrigendum to the original paper. However, pDC were depleted in only 121	  
60% of the mice, and how long the depletion lasted after each DT injection was not shown. This 122	  
is of particular relevance given that DT was only administered once per week. In addition, 123	  
depletion efficacy in the aorta was not assessed at this later time point. As discussed above, it 124	  
would have been fundamental to evaluate the efficacy and kinetics of pDC depletion in all target 125	  
organs throughout the duration of the experiment. This represents a limitation of the study given 126	  
that previous studies were unable to provide conclusive evidence of effective and continuous 127	  
long-term pDC depletion in BDCA2-DTR mice. 128	  
Similarly, it would have been important to assess selectivity of the depletion in atherosclerotic 129	  
mice following 12 weeks of HFD. pDCs are acutely and selectively depleted in BDCA2-DTR 130	  
mice in both aorta and spleen in the steady state. However, on one hand, TLR7/9 agonists have 131	  
been shown to downregulate pDCs expression of BDCA2 (14), suggesting that activated pDCs 132	  
in advanced atherosclerotic vessels may be less susceptible to depletion; on the other hand, the 133	  
truncated human BDCA-2 promoter could give rise to off-target DTR expression, particularly in 134	  
the advanced stages of atherosclerosis, where promiscuous expression of BDCA-2 by other 135	  
leukocyte subsets may occur. 136	  
 137	  
Toxic and Off-target Effects of DT-treatment 138	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Importantly, controls for the DT treatment were not entirely adequate. Eight weeks following 139	  
chimera generation, Ldlr-/-:BDCA2-DTR mice were fed HFD and injected with PBS or DT for 140	  
the subsequent 12 weeks. Treatment with mutant DT or DT-treated Ldlr-/-:WT-DTR- chimeric 141	  
mice were not used as controls to assess any potential toxicity related to DT treatments, as 142	  
conventionally performed (15, 16). Mice are generally resistant to DT, however, several reports 143	  
highlight potential DT toxic effects (17) and development of anti-DT antibodies has been 144	  
reported (18). In addition, off-target effects have been observed following DT-injection. For 145	  
example, CD11c-DTR and CD11c-DOG mice developed neutrophilia 24h after DT 146	  
administration, which is independent from DC depletion (19). Moreover, ectopic DTR 147	  
expression in DTR Tg mouse models may also lead to toxic effects of DT. For example, DT has 148	  
been shown to be lethal in Zbtb46-DTR mice, due to aberrant expression of Zbtb46 in erythroid 149	  
progenitors and endothelial cells (20). 150	  
In a similar experimental setting to Yun et al. (9), Biessen and coworkers observed no 151	  
significant changes in lesion formation in Ldlr-/-:BDCA2-DTR mice fed HFD and injected with 152	  
DT or mutant DT (120 ng/mouse 3 times per week, i.p.) for 3 weeks (unpublished data). The 153	  
experiment was terminated due to significant decrease in body weight and granulocytosis 154	  
observed in blood and spleen of DT-depleted mice at end point. These data confirm the 155	  
importance to adequately control DT administration in experiments with DTR Tg mice. 156	  
 157	  
Merits and Pitfalls of the Mechanistic Studies 158	  
Finally, the authors found that mouse and human aortic pDCs expressed the tolerogenic enzyme 159	  
indoleamine 2,3-dioxygenase (IDO)-1, suggesting an activated/matured pDC phenotype. 160	  
Furthermore, they propose a direct functional link between the presence of IDO-1+ pDCs and 161	  
Treg generation in the diseased vessel. These data align with several earlier findings, including 162	  
in the context of atherosclerosis, Daissormont et al. (3). However, both the latter study and that 163	  
of Yun et al. (9) provided no demonstration of a direct effect of pDCs or IDO expression by 164	  
pDCs on vascular Tregs in vitro or in vivo. Firstly, the authors show an interesting correlation 165	  
between aortic pDCs and Treg numbers with disease progression. Secondly, they demonstrate 166	  
reduced Treg numbers in Ido1-/- mice compared to WT. However, in Ido1-/- mice the knock out 167	  
effect is not pDC restricted/specific and therefore, we cannot rule out potential contributions 168	  
from other leukocyte subsets known to express IDO, such as conventional DCs, macrophages 169	  
and smooth muscle cells. Finally, the authors demonstrate that depletion of pDCs in 170	  
atherosclerotic mice resulted in reduction of aortic Tregs. These findings are interesting; 171	  
however, implications difficult to interpret given that no data on other T cell subsets were 172	  
shown. Similarly, the authors demonstrate that antigen presentation by pDCs induced OVA-173	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specific Tregs in the aorta of Ldlr-/-:OT-II chimeras. MHC class II-restricted antigen 174	  
presentation by pDCs may lead to the expansion of all CD4+ Tg T cell subsets (that have not 175	  
been investigated) and the effect may not therefore be restricted to Tregs. 176	  
 177	  
Lessons Learned and Proposed Next Steps 178	  
The above-discussed limitations highlight the importance to deplete specifically and 179	  
continuously pDCs in vivo. All the genetically modified mouse models developed to date 180	  
present limitations and therefore, new selective, reproducible and advanced tools are urgently 181	  
required. pDCs may act in an immunogenic or tolerogenic manner in atherosclerosis depending 182	  
on the specific anatomical niche, the local inflammatory environment and the different stages of 183	  
the pathology. Understanding the delicate balance between pDC-driven immunogenic and 184	  
tolerogenic response(s) is therefore becoming increasingly crucial. At the same time, it would 185	  
be key to understand the net contribution of vascular vs. systemic pDCs to disease development 186	  
and progression and investigate why several leukocytes acquire a ‘pDC like’ phenotype in 187	  
atherosclerotic arteries. As these studies progress we will learn more about whether pDCs are 188	  
indeed viable diagnostic, prognostic and/or therapeutic targets in atherosclerosis. 189	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